Navigation Links
Daiichi Sankyo, Inc. Acquires First US-Based Packaging and Manufacturing Facility
Date:2/15/2011

PARSIPPANY, N.J., Feb. 15, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI), today announced the acquisition of a 140,000 square foot facility in Bethlehem Township, Pennsylvania from Amcor, a global packaging manufacturer. This acquisition, worth $10.25MM, enables DSI to leverage existing resources to more cost-effectively supplement its operations rather than build a new facility. The facility is expected to be operational in the summer or early fall of 2011 and is expected to package some of company's portfolio of marketed products, such as Benicar®, Welchol® and Azor®. Once the facility is operating at full capacity, it is expected to assume an increasing responsibility for packaging the entire line of marketed products in the U.S., as well as perform compounding operations for select products.

"Creating and protecting family-sustaining jobs in Pennsylvania is one of this administration's highest priorities, so I'm pleased to announce Daiichi Sankyo's decision to select PA as the site for its first-ever U.S. packaging and manufacturing plant," said Governor Corbett.  "By creating approximately 80 jobs, continuing the productive use of a facility that would otherwise have been closed, and injecting more than $15 million in outside investment into the local economy, this project will have a definite positive impact on the Lehigh Valley region."

DSI conducted a comprehensive national site search with McCallum Sweeney Consulting to identify an existing facility that mirrored the company's packaging goals and specifications. After a national screening of 62 sites in 48 communities in 12 states, the company selected the site in Bethlehem. Upon completing the initial phase of the renovation, DSI plans to hire approximately 80 new employees and will create a positive economic impact through related purchasing of goods and services from local businesses.

"This acquisition diversifies our company's capabilities and allows us to streamline our operations and minimize commercialization risk by exerting greater control over the life cycle of our products, from research and development through packaging and distribution," said Jeff Lane, Vice President of Operations, Daiichi Sankyo, Inc. "We are excited to be opening a facility in Bethlehem and look forward to a productive future working relationship and becoming a part of the local community. The Governor's Action Team, Lehigh Valley Economic Development Corporation, the Northampton County and City of Bethlehem were invaluable partners in helping to make this milestone possible."

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.


'/>"/>
SOURCE Daiichi Sankyo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
6. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
7. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
10. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
11. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
Breaking Medicine News(10 mins):